Securities Registration: Employee Benefit Plan (s-8)
February 14 2017 - 6:08PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on February 14, 2017
Registration
No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
33-0969592
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. employer
identification no.)
|
|
|
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania
|
|
19462
|
(Address of principal executive offices)
|
|
(Zip code)
|
2007 Omnibus Incentive Plan
(Full title of the plan)
J. Joseph Kim, Ph.D.
President and Chief Executive Officer
Inovio Pharmaceuticals, Inc.
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania 19462
(267)
440-4200
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
John W. Kauffman, Esq.
Duane Morris LLP
30
South 17th Street
Philadelphia, PA 19103
(215)
979-1227
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated
filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of securities
to be registered
|
|
Amount
to be
registered (1)(2)
|
|
Proposed
maximum
offering price
per share(3)
|
|
Proposed
maximum
aggregate
offering price(3)
|
|
Amount of
registration fee(3)
|
Common Stock, $0.001 par value
|
|
513,833 shares
|
|
N/A
|
|
$3,334,776.17
|
|
$386.51
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional securities that may be offered or issued in connection
with any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the outstanding number of shares of Common Stock.
|
(2)
|
Represents 513,833 additional shares of Common Stock authorized to be issued under the Registrants 2007 Omnibus Incentive Plan (the 2007 Plan). The Registrant previously registered shares available for
issuance under the 2007 Plan on registration statements on Form
S-8
filed with the Securities and Exchange Commission on May 14, 2007, May 9, 2008, August 26, 2009, May 18, 2010,
May 20, 2011, May 18, 2012, November 13, 2013, May 28, 2014 and January 28, 2016 (Registration Nos.
333-142938,
333-150769,
333-161559,
333-166906,
333-174353,
333-181532,
333-192318,
333-196325
and
333-209155,
respectively).
|
(3)
|
Pursuant to Rule 457(h), the maximum aggregate offering price was calculated by adding 513,833 shares issuable under the 2007 Plan, for a total of 513,833 shares, multiplied by the price of $6.49 per share based on the
average of the high and low sale prices for the Registrants Common Stock as reported on the NASDAQ Stock Market on February 10, 2017, which is a date within five business days prior to the filing of this registration statement, as
reported on the NASDAQ Stock Market.
|
INTRODUCTORY NOTE
This Registration Statement relates solely to the registration of additional securities of the same class as other securities for which a
registration statement on this form relating to an employee benefit plan is effective. Pursuant to General Instruction E of Form
S-8,
this Registration Statement hereby incorporates by reference the contents
of the registration statements on Form
S-8
the Registrant filed on May 14, 2007, May 9, 2008, August 26, 2009, May 18, 2010, May 20, 2011, May 18, 2012, November 13, 2013,
May 28, 2014 and January 28, 2016 (Registration Nos.
333-142938,
333-150769,
333-161559,
333-166906,
333-174353,
333-181532,
333-192318,
333-196325
and
333-209155,
respectively).
|
|
|
Exhibit
No.
|
|
Description of Exhibit
|
|
|
5.1
|
|
Opinion of Duane Morris LLP
|
|
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm
|
|
|
23.2
|
|
Consent of Duane Morris LLP (included in Exhibit 5.1)
|
|
|
24.1
|
|
Powers of Attorney (included in signature pages)
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form
S-8
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Plymouth Meeting, Pennsylvania on
February 14, 2017.
|
|
|
INOVIO PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ J. Joseph Kim
|
|
|
J. Joseph Kim
|
|
|
President and Chief Executive Officer
|
Know all men by these presents, that each person whose signature appears below constitutes and appoints
J. Joseph Kim and Peter Kies, and each or either of them, as such persons true and lawful
attorneys-in-fact
and agents, with full power of substitution, for such
person, and in such persons name, place and stead, in any and all capacities to sign any or all amendments or post-effective amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact
and agents full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact
and agents, or any of them or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, the registration statement has been signed by the following persons in the
capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Avtar Dhillon
Avtar Dhillon
|
|
Chairman of the Board of Directors
|
|
February 14, 2017
|
|
|
|
/s/ J. Joseph Kim
J. Joseph Kim
|
|
President, Chief Executive Officer and Director (principal executive officer)
|
|
February 14, 2017
|
|
|
|
/s/ Peter Kies
Peter Kies
|
|
Chief Financial Officer (principal financial and principal accounting officer)
|
|
February 14, 2017
|
|
|
|
/s/ Simon X. Benito
Simon X. Benito
|
|
Director
|
|
February 14, 2017
|
|
|
|
/s/ Angel Cabrera
Angel Cabrera
|
|
Director
|
|
February 14, 2017
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Morton Collins
Morton Collins
|
|
Director
|
|
February 14, 2017
|
|
|
|
/s/ Adel A.F. Mahmoud
Adel A.F. Mahmoud
|
|
Director
|
|
February 14, 2017
|
|
|
|
/s/ David Weiner
David Weiner
|
|
Director
|
|
February 14, 2017
|
|
|
|
/s/ Nancy J. Wysenski
Nancy J. Wysenski
|
|
Director
|
|
February 14, 2017
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description of Exhibit
|
|
|
5.1
|
|
Opinion of Duane Morris LLP
|
|
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm
|
|
|
23.2
|
|
Consent of Duane Morris LLP (included in Exhibit 5.1)
|
|
|
24.1
|
|
Powers of Attorney (included in signature pages)
|
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024